New trials, publications, preprints and grants on this target, month by month.
Publication
A false sense of hypoxia: Pro‑tumorigenic VHL‑HIF2α dysregulation in clear cell renal cell carcinoma (Review).
23 Oct 2026· Molecular medicine reports· PUBMED
Publication
Discovery of Potent and Selective VHL-Recruiting PROTAC Degraders Targeting EGFR with Improved Developability and Potent Anti-NSCLC Efficacy.
8 Oct 2026· Journal of medicinal chemistry· PUBMED
Trial
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Targeting the nonenzymatic scaffold function of RIPK1 via a VHL-recruiting PROTAC synergizes with immunotherapy in melanoma.
29 Sept 2026· European journal of medicinal chemistry· PUBMED
Preprint
Combined Loss of VHL and TSC1 Drives Clear Cell Renal Cell Carcinoma with Metabolic and Redox Reprogramming that Creates an NRF2 Dependency.
28 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics.
9 Sept 2026· Biomarker research· PUBMED
Publication
4-2 VHL-Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas-Mediated IL-17 Signaling.
1 Sept 2026· Drug development research· PUBMED
Publication
Exosomal miR-21-5p from ectopic endometrial stromal cells drives fibrosis progression in endometriosis through direct VHL targeting.
12 Aug 2026· Human cell· PUBMED
Publication
Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancer.
30 Jul 2026· Frontiers in oncology· PUBMED
Publication
Downregulation of PHB1 due to Loss of VHL Protein Expression Promotes the Malignancy Progression of Kidney Renal Clear Cell Carcinoma.
24 Jul 2026· Frontiers in bioscience (Landmark edition)· PUBMED
Publication
Case Report: Diagnosis and treatment report and literature review of 2 cases of VHL-deficient renal cell carcinoma.
21 Jul 2026· Frontiers in oncology· PUBMED
Publication
Targeting enolase isoenzyme 2 enables precision glycolysis inhibition in VHL-mutant renal cell carcinoma.
14 Jul 2026· Cell death & disease· PUBMED
Publication
GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency.
5 Jul 2026· Journal of medicinal chemistry· PUBMED
Publication
Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma.
1 Jul 2026· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publication
YTHDC2 suppresses oral squamous cell carcinoma progression by inhibiting glutaminolysis via VHL/HIF-1α axis.
29 Jun 2026· International journal of biological macromolecules· PUBMED
Preprint
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small Molecules.
29 May 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Reduced Circulating HIF-1α, HIF-2α, HIF-3α, and VHL Levels in Patients With Pulmonary Arterial Hypertension.
21 May 2026· Pulmonary circulation· PUBMED
Publication
Natural Products in Clear Cell Renal Cell Carcinoma: Rewiring the VHL-HIF Axis, Metabolic Plasticity, and Tumor-Immune Interactions.
20 May 2026· International journal of molecular sciences· PUBMED
Publication
First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493).
18 May 2026· Theranostics· PUBMED
Trial
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
12 May 2026· PHASE3 · RECRUITING· CTIS
Preprint
PBRM1-VHL cooperation rewires lipid and iron metabolism to promote ferroptosis resistance in clear cell renal cell carcinoma.
6 May 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation.
6 May 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
Clear Cell Chondrosarcoma With Somatic VHL Inactivation: A Case Report With Integrated Genomic and Transcriptomic Analysis.
1 May 2026· Genes, chromosomes & cancer· PUBMED
Publication
Degrading TBK1 to disarm VHL-deficient renal cancer.
16 Apr 2026· Cell chemical biology· PUBMED
Publication
Dual FDG and Octreotide PET/CT Imaging in a Patient With Malignant Pheochromocytoma and VHL Gene Mutation.
15 Apr 2026· Clinical nuclear medicine· PUBMED
Publication
CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver.
15 Apr 2026· Molecular cancer· PUBMED
Publication
VHL-recruiting PROTAC attenuates AKI-CKD transition via simultaneous degradation of Smad3 and stabilization of HIF-2α.
10 Apr 2026· Cell death & disease· PUBMED
Publication
Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma.
8 Apr 2026· Cancer communications (London, England)· PUBMED
Publication
Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL.
31 Mar 2026· Discover oncology· PUBMED
Publication
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.
12 Mar 2026· Nature communications· PUBMED